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General Introduction
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Primary cutaneous T-cell lymphoma
The term primary cutaneous lymphoma refers to 
clonal proliferations of neoplastic lymphocytes 
presenting in the skin with no evidence of extra-
cutaneous disease at time of diagnosis. Whereas 
most lymphomas develop in lymph nodes, a 
considerable proportion primarily involves 
extranodal sites. After the gastrointestinal tract, 
the skin is the second most common site of 
extranodal non-Hodgkin’s lymphoma with an 
estimated annual incidence of 1 per 100.000 
persons.1 Primary cutaneous lymphomas often 
have a different clinical behavior and prognosis 
than nodal lymphomas of the same histological 
subtype. Lymphoma cells of nodal and primary 
cutaneous origin not only differ in the expres-
sion of organ-speciﬁc homing receptors, but also 
with respect to the occurrence of genetic lesions 
such as speciﬁc chromosomal translocations.1,2 
Based on the immunophenotypical character-
istics of the neoplastic lymphocytes two major 
subgroups of primary cutaneous lymphomas are 
distinguished: primary cutaneous T-cell lym-
phomas (CTCL) that account for approximately 
75% of cases and primary cutaneous B-cell lym-
phomas (CBCL) accounting for the remaining 
25%. Clinical, histopathological, genetic and 
epigenetic aspects of CTCL are the subject of 
this thesis. 
Classiﬁcation of primary cutaneous 
lymphomas
A unique feature of cutaneous lymphomas is the 
fact that different clinical manifestations and 
disease stages are visible to the eye and easily 
accessible for histopathologic and molecular 
genetic study, thus allowing correlation 
between clinical appearance, disease behaviour, 
histopathology and genetic alterations. This 
approach has been taken to delineate distinct 
disease entities which have been included in 
the European Organization for Research and 
Treatment of Cancer (EORTC) for primary 
cutaneous lymphomas and the World Health 
Organization (WHO) classiﬁcation.1,3 Accurate 
classiﬁcation is signiﬁcant from a clinical point 
of view since it dictates the management of 
patients with cutaneous lymphoma. Recently 
a new classiﬁcation system for cutaneous 
lymphomas was presented: the WHO-EORTC 
classiﬁcation.4 Table 1 shows the WHO-EORTC 
classiﬁcation of cutaneous lymphomas including 
the relative frequency and the actuarial 5-year 
survival rate of the different disease entities. 
The characteristics of CTCLs that have been 
the subject of studies included in this thesis are 
described in more detail below.
Mycosis Fungoides
Mycosis fungoides (MF) is a mature T-cell lym-
phoma presenting in the skin with erythematous 
patches, plaques or tumors and is characterized 
histopathologically by epidermal and dermal 
inﬁltration of neoplastic T cells with cerebri-
form nuclei. MF is the most common type of 
CTCL and accounts for approximately half of 
all primary cutaneous lymphomas (see Table 
1).4 MF typically affects older adults and occurs 
more frequently in males than in females. The 
initial skin lesions are erythematous, slightly 
scaly patches and thin plaques that are com-
monly located on the trunk. MF generally has 
an indolent disease course with subsequent evo-
lution of limited patches to more widespread 
and inﬁltrated plaques over a period of years 
to decades. The disease may present with or 
progress towards more advanced forms, with 
development of skin tumors and dissemination 
of malignant T cells to lymph nodes and internal 
organs. Various cutaneous manifestations of MF 
are shown in Figure 1. Although MF behaves 
as a low-grade lymphoma with an apparent ten-
dency to progress, actual disease progression 
with development of skin tumors and potentially 
lethal extracutaneous dissemination occurs in 
only a subset of patients. The clinical stage of 
MF is determined according to the nature and 
distribution of the skin lesions (limited or gen-
eralized patches/plaques, skin tumors or eryth-
roderma) and the presence of lymph node or 
visceral involvement.5-7
Histopathologically, patch/plaque stage disease 
is characterized by the presence of mononuclear 
cells with hyperchromatic, cerebriform nuclei 
and admixed inﬂammatory cells in the papil-
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Table 1. WHO-EORTC classification of cutaneous lymphomas 
WHO-EORTC Classification 
Frequency
(%)#
Disease-specific 
5-year survival 
(%)
CUTANEOUS T-CELL LYMPHOMA 
Indolent clinical behaviour 
Mycosis fungoides 
Folliculotropic MF 
Pagetoid reticulosis 
Granulomatous slack skin  
Primary cutaneous anaplastic large cell lymphoma 
Lymphomatoid papulosis 
Subcutaneous panniculitis-like T-cell lymphoma  
Primary cutaneous CD4+ small/medium pleomorphic T-cell 
lymphoma*
Aggressive clinical behaviour 
Sézary syndrome 
Primary cutaneous NK/T-cell lymphoma, nasal-type  
Primary cutaneous aggressive CD8+ T-cell lymphoma *
Primary cutaneous �/� T-cell lymphoma *
Primary cutaneous peripheral T-cell lymphoma, unspecified $
CUTANEOUS B-CELL LYMPHOMA
Indolent clinical behaviour 
Primary cutaneous marginal zone B-cell lymphoma  
Primary cutaneous follicle center  lymphoma 
Intermediate clinical behaviour
Primary cutaneous diffuse large B-cell lymphoma, leg type 
Primary cutaneous diffuse large B-cell lymphoma, other 
Intravascular large B-cell lymphoma 
44
4
<1
<1
8
12
1
2
3
<1
<1
<1
2
7
11
4
<1
<1
88
80
100 
100 
95
100 
82
75
24
NR
18
NR
16
99
95
55
50
65
# Data are based on 1905 patients with a primary cutaneous lymphoma registered at the Dutch and Austrian 
Cutaneous Lymphoma Group between 1986 and 2002
$ Primary cutaneous T-cell lymphoma, unspecified excluding the three provisional entities indicated with an 
asterisk (*); NR: not reached 
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lary dermis and the epidermis (epidermotro-
pism).8 Pautrier’s microabscesses, collections of 
neoplastic T cells in the epidermis, are highly 
characteristic of MF. The neoplastic cells in MF 
have a mature CD3+, CD4+, CD8-, CD45RO+ 
memory T cell immunophenotype. Expression 
of the cell surface markers CD2, CD5 and CD7, 
present on benign mature T cells, may be lost on 
neoplastic T cells.9 Progression to tumor-stage 
MF is characterized by a loss of epidermotro-
pism, an increase in the density of tumor cells 
in the dermis and is frequently associated with 
the acquisition by malignant T cells of a blast 
cell appearance. In Figure 1 characteristic histo-
pathological features of MF are shown. 
Patients presenting with localized patches or 
plaques are known to have an excellent prog-
nosis and have a life expectancy that is similar 
to that of a matched control population.10 In 
patients presenting with more widespread 
plaques or skin tumors, the disease course is less 
favorable. The clinicopathological and biologi-
cal determinants of the rate of disease progres-
sion of patients with MF are largely unknown. 
MF conﬁned to the skin is commonly treated 
with skin-directed therapies, including topical 
steroids, PUVA photochemotherapy, UV-B 
phototherapy, topical nitrogen mustard or total 
skin electron beam irradiation.11 Patients may 
also receive combination treatments consisting 
of PUVA photochemotherapy with systemic 
retinoids (acitretine, bexarotene) or interferon-
alpha. Local radiotherapy is traditionally used to 
treat skin tumors and multi-agent chemotherapy 
is generally used only in case of extracutaneous 
involvement.12 Experimental and less studied 
interventions include autologous and allogeneic 
peripheral stem cell transplantation, recombi-
nant fusion protein combining diphtheria toxin 
and interleukin-2, interleukin-12, imiquimod 
cream, pegylated liposomal doxorubicin, anti-
CD4 and anti-CD52 monoclonal antibodies, the 
synthetic deoxynucleotide CpG7909 and the 
histone deacetylase inhibitors depsipeptide and 
suberoylanilide hydroxamic acid.13-17
Folliculotropic mycosis fungoides
Many clinical and histologic subtypes of MF 
have been reported.18 In the WHO-EORTC 
classiﬁcation, folliculotropic MF (also termed 
follicular MF) has been categorized as a sepa-
rate entity.4 Folliculotropic MF is characterized 
histopathologically by the presence of follicu-
lotropic inﬁltrates often with sparing of the epi-
dermis, and clinically by preferential involve-
ment of the head and neck area with pruritic 
follicular papules and nodules. Most cases show 
mucinous degeneration of the hair follicles (fol-
licular mucinosis) and were designated as MF-
associated follicular mucinosis in the EORTC 
classiﬁcation.1,19 Similar cases, but without fol-
licular mucinosis have been reported as follicu-
locentric or pilotropic MF.20 In folliculotropic 
MF, malignant T cells are located around follic-
ular structures, often sparing the epidermis. In 
contrast, the classic type of MF is characterized 
histopathologically by neoplastic T cells that are 
epidermotropic and located sub- or intra-epider-
mally. Clinical experience has learned that fol-
liculotropic MF is more refractory to treatment 
and has a worse prognosis than classic MF. This 
and the often typical clinicopathologic presen-
tation have been the main reasons for its clas-
siﬁcation as a separate disease entity. Treatment 
of folliculotropic MF usually consists of PUVA 
photochemotherapy, sometimes in combina-
tion with retinoids or interferon-alpha, or total 
skin electron beam radiotherapy. Nodular skin 
lesions that are resistant to treatment are com-
monly treated with local radiotherapy. Shown 
in Figure 1 are typical clinical and histological 
features of folliculotropic MF. 
Sézary sydrome
Sézary syndrome (Sz) is deﬁned historically by 
the triad of erythroderma, generalized lymph-
adenopathy, and the presence of neoplastic T 
cells (Sézary cells) in skin, lymph nodes and 
peripheral blood.21,22 Severe pruritus, ectropion, 
alopecia, palmoplantar keratoderma and gener-
alized immunosuppression are common associ-
ated features. Sz is generally considered to be a 
leukemic variant of MF due to the similarity of 
their histopathological and immunophenotypical 
features.23 Sz is a more aggressive CTCL with 
an estimated 5-year-survival rate of 24%.4 More 
than MF and other CTCL, Sz is characterized 
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Figure 1. Photographs of clinical and pathologic manifestations of various CTCLs.
a1) Plaque-stage MF, a2) Histopathological aspect of plaque-stage MF,
b1) Tumor-stage MF, b2) Histopathological aspect of tumor-stage MF,
c1) Folliculotropic MF, c2) Histopathological aspect of folliculotropic MF.
Figure 1. Photographs of clinical and pathologic manifestations of var ou  CTCLs.
a1) Plaque-stage MF, a2) Histopathological spect of pl que-stage MF,
b1) Tumor-stage MF, b2) Histopathological spect of tumor- tage MF,
c1) Folliculotropic MF, c2) Histopathological spect f folliculotropic MF,
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Figure 1. continued
d1) Primary cutaneous anaplastic large cell lymphoma, d2) Histopathological aspect,
e1) Lymphomatoid papulosis, e2) CD30-positive cells in a lymphomatoid papulosis lesion,
f) Sézary syndrome, g) Primary cutaneous peripheral T-cell lymphoma unspecified.
Figure 1 continued. 
d1) Primary cutaneous anaplastic l rge cell lymphoma, d2) Histopathological aspect,
e1) Lymphomat id papulosis, e2) CD30-positive cells in a lymphomato d papulosis lesion,      
f) Sézary syndrome, g) Primary cutaneous peripheral T-cell lymphoma unspeciﬁed.
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by systemic immunosuppression. As a conse-
quence opportunistic infections often occur and 
are an important cause of death of patients with 
Sz. Although current treatments of Sz, including 
chemotherapy and extracorporal photophere-
sis, have some efﬁcacy, the prognosis generally 
remains poor.
Primary cutaneous anaplastic large cell 
lymphoma
Primary cutaneous anaplastic large cell lym-
phoma (C-ALCL) is an indolent lymphoma that 
generally presents with one solitary or few clus-
tered skin tumors. Histopathologically C-ALCL 
is characterized by a dense dermal inﬁltrate com-
posed of large cells with an anaplastic or pleo-
morphic cytomorphology and expression of the 
CD30 antigen by the majority of tumor cells.24 
In the EORTC classiﬁcation this lymphoma was 
designated as primary cutaneous CD30+ large T-
cell lymphoma (CD30+ LTCL), and this condi-
tion will be referred to as such in some chapters 
of this thesis. C-ALCL and lymphomatoid papu-
losis are considered as parts of a spectrum of 
primary cutaneous CD30-positive lymphopro-
liferative disorders. Lymphomatoid papulosis is 
a chronic, recurrent, self-healing papulonecrotic 
or papulonodular skin disease with histologic 
features suggestive of C-ALCL. Also in patients 
with C-ALCL tumors may disappear spontane-
ously. This CTCL rarely disseminates to extra-
cutaneous sites and has an excellent prognosis 
with a disease-speciﬁc 5-year-survival of 96%.24 
Whether signaling through the CD30 receptor 
itself contributes to the indolent behavior of this 
lymphoma is still a matter of debate.25 Radio-
therapy or surgical excision is the ﬁrst choice of 
treatment in patients presenting with a solitary 
or few localized tumors. In case of multifocal 
skin lesions patients may be treated with low 
dose methotrexate, whereas patients are usually 
only treated with multi-agent chemotherapy in 
case of extracutaneous dissemination. 
Primary cutaneous  peripheral T-cell lym-
phoma unspeciﬁed
Primary cutaneous peripheral T-cell lymphoma 
(PTL) unspeciﬁed represents a heterogeneous 
group that includes all T-cell neoplasms that 
do not ﬁt into any of the other deﬁned subtypes 
of CTCL. In the WHO-EORTC classiﬁcation 
primary cutaneous CD4+ small/medium pleo-
morphic T-cell lymphoma, primary cutaneous 
aggressive CD8+ T-cell lymphoma and primary 
cutaneous gamma/delta T-cell lymphoma are rec-
ognized as provisional entities within the group 
of PTL unspeciﬁed (Table 1). In the EORTC-
classiﬁcation, the term primary cutaneous 
CD30-negative large T-cell lymphoma (CD30- 
LTCL) was used to designate most entities now 
referred to as PTL unspeciﬁed and in some 
chapters of this thesis the term CD30- LTCL is 
still used.1,26 These lymphomas usually present 
with generalized tumors and have an aggressive 
behavior. Rapid development of generalized 
skin lesions is more common than in C-ALCL. 
The estimated 5-year survival of patients with 
a CTCL categorized as PTL unspeciﬁed is 
approximately 16%.4
Pathogenetic aspects of cutaneous T-cell 
lymphoma
Phenotype of malignant T-cells in CTCL
Malignant cells in CTCL skin lesions typically 
have a CD4+, CD8-, CD45RO+, CLA+, CCR4+, 
CXCR3+, activated, memory, skin-homing T 
cell phenotype. These clonal neoplastic T cells 
retain many characteristics of their benign 
counterparts, including aspects of their growth 
regulation and their propensity to home to the 
skin. Normally skin-homing T cells have a 
role in skin immune surveillance and make up 
30% of circulating memory T cells. Following 
injury or infection of the skin, epidermal den-
dritic cells (Langerhans cells) are activated and 
migrate to the local skin-draining lymph nodes. 
Upon encounter with a naïve CD4+ T cell that 
speciﬁcally recognizes antigen presented by this 
dendritic cell, activation of the T cell with rapid 
clonal expansion ensues. During the process of 
activation, CD4+ T cells differentiate into either 
T helper 1, T helper 2 or T regulatory cells, T 
cell subsets with distinct cytokine expression 
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proﬁles and effector functions.27 The generated 
antigen-speciﬁc T cells acquire the ability to 
home to the original site of inﬂammation, the 
skin. The interactions of skin-homing T cells 
with dermal capillary cells that facilitate extrav-
asation and skin-homing capacity are conferred 
by expression on the cell membrane of CLA and 
the chemokine receptor CCR4, that interact with 
E-selectin and the chemokines CCL17 (TARC) 
and CCL22 (MDC) respectively on endothelial 
cells.28,29 The afﬁnity of skin-homing T cells for 
the epidermis and superﬁcial dermis is further-
more mediated by expression of CXCR3, a che-
mokine receptor that binds to CXCL10 (IP-10) 
and CXCL11 (IP-9/I-TAC) produced by basal 
keratinocytes.30 
It has been assumed that malignant T cells in 
the early phase of MF proliferate in response 
to chronic stimulation by antigen present in 
the skin. This assumption is based on the 
observation that the malignant T cells have a 
CD45RO+ memory phenotype and are often 
found adjacent to antigen-presenting dendritic 
cells (sub)epidermally in the classic type of MF 
or inﬁltrating follicular epithelium in follicu-
lotropic MF.31-33 Particularly in its early stages 
CTCL may therefore be considered as a group 
of diseases characterized by altered immune 
biology resulting from defective regulation of 
clonal T-cell expansion. During disease evo-
lution the dependence of malignant T cells on 
antigenic stimulation is assumed to diminish 
and growth to become more autonomous.
Similar to other malignancies the neoplastic T 
cells in CTCL are primarily characterized by 
dysregulation of proliferation. Under physi-
ological circumstances T cells are programmed 
to undergo rapid clonal expansion upon recogni-
tion of antigen, through activation of signaling 
cascades triggered by the T cell receptor and the 
interleukin-2 receptor. Because of the enormous 
potential for proliferation of a T cell upon activa-
tion, the size of the expanding lymphocyte clone 
is regulated tightly.34,35 Homeostasis of clonally 
expanding T cells is mainly exerted through 
elimination of excessive T cells: once antigen-
activated T cells have gone through several cell 
cycles, they become exquisitely susceptible to 
apoptosis.36 If there is no further antigen stimu-
lation, passive, lymphokine-withdrawal apop-
tosis follows. In contrast, if cycling T cells are 
repeatedly stimulated by antigen, so called acti-
vation-induced cell death occurs. At the conclu-
sion of the contraction phase that follows clonal 
expansion, only a small number of memory T 
cells persist in secondary lymphoid organs and 
peripheral tissues. The cell surface receptor Fas 
(CD95) and Fas ligand are key regulators of 
mature T cell apoptosis and play a central role 
in the process of activation-induced cell death.37 
CTCL is characterized by unrestricted expan-
sion of a clone of skin-homing T cells. Given the 
importance of apoptosis in controlling the size 
of activated T-cell clones, it may be suspected 
that disruption of apoptosis signaling has an 
important role in the pathogenesis of CTCL. 
Genetic factors in the pathogenesis of CTCL
Similar to other types of cancer, DNA lesions 
are primarily responsible for the development of 
CTCL. Alterations in the genome of cancer cells 
lead to increased activity of oncogenes and inac-
tivation of tumor suppressor genes, which drives 
the neoplastic process mainly by stimulation of 
cellular proliferation and by inhibition of apop-
tosis.38 Additionally, cancer cells often exhibit 
genomic instability and capacity to metastasize. 
Oncogene activation can result from chromo-
somal translocation, ampliﬁcation or activating 
mutations. Tumor suppressor genes are mostly 
inactivated through chromosomal deletions, 
inactivating mutations or promoter hypermeth-
ylation.39 During evolution of the disease, also 
due to genomic instability, DNA lesions accu-
mulate, cellular heterogeneity develops and 
more malignant subclones emerge.40
Cytogenetic studies have revealed the occur-
rence of many structural and numerical chro-
mosomal abnormalities in malignant T cells 
of patients with CTCL, in particular in Sz and 
advanced stages of MF. The following chromo-
somal alterations have been reported to occur at 
a high frequency: deletions on 1p, 10q, 17p, 19 
and ampliﬁcations on 4q, 17q and 18.41-48 CTCL 
has not been associated with a single mutation 
or chromosomal alteration, nor have recurrent 
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chromosomal translocations been identiﬁed. 
In addition to chromosomal instability, micro-
satellite instability has been demonstrated in 
malignant T cells of a subset of patients with 
advanced MF.49,50 Genomic instability there-
fore is a hallmark of CTCL, already occurring 
in early stages of the disease.41,48 The resulting 
acquisition of chromosomal alterations and 
mutations in the T cell genome is considered 
as an important intrinsic factor driving disease 
progression by allowing the emergence of more 
aggressive subclones.
Genes affected by chromosomal alteration, muta-
tion or promoter hypermethylation presumed to 
be implicated in the pathogenesis of CTCL are 
listed in Table 2. Among tumor suppressor genes 
affected in CTCL are the CDKN2A gene encod-
ing the p16(INK4A) protein, TP53, Fas, MLH1, 
PTEN, TGF-beta receptor I and II genes. Inacti-
vation of p16(INK4A), either through chromo-
somal deletion or promoter hypermethylation, 
occurs in a substantial percentage of CTCL cases 
and has been associated with tumor progression 
of MF.51-53 Point mutations in the TP53 gene 
were found at a low frequency in two studies and 
could not be detected in three other studies.53-57 
More recently, point mutations in the Fas gene 
have been reported in MF, although at a low fre-
quency.57,58 In tumor cells from a patient with 
progressed CTCL, a mutation in the TGF-beta 
receptor II gene has been demonstrated that 
dominantly inhibits the function of the wild-type 
receptor.59 In addition, an inactivating deletion 
in the TGF-beta receptor I gene was shown in 
a tumor cell line from a patient with C-ALCL.60 
Gene ampliﬁcation and overexpression of JUNB, 
a negative regulator of cellular proliferation, has 
been found in MF, Sz and C-ALCL.61,62 Para-
doxically the BCL2 gene, that functions as an 
inhibitor of apoptosis and is often overexpressed 
in B-cell lymphomas, has been reported to be 
frequently deleted in CTCL.62 
Table 2. Overview of genetic and epigenetic lesions reported in CTCL
Gene Mechanism Entity Frequency Effect Reference
BAX Point mutation MF 0/44 (0%) Diminished susceptibility
to apoptosis
Dereure57
BCL2 Chromosomal deletion MF, Sz
C-ALCL
17/42 (40%)
3/13 (23%)
Disruption of intrinsic
apoptosis pathway;
altered susceptibility to
apoptosis
Mao62
BCR Amplification MF, Sz 4/7 (57%) Serine/threonine kinase
activity
Mao61
CDKN2A,
p16(INK4A)
Chromosomal deletion
Promoter hypermethylation
Chromosomal deletion
Promoter hypermethylation
Promoter hypermethylation
MF
MF
MF, Sz
4/13 (31%)
8/13 (62%)
9/49 (18%)
13/49 (27%)
19/66 (29%)
Diminished CDK
inhibitor activity, cell
cycle deregulation
Navas51
Navas53
Scarisbrick52
CDKN2A,
p14(ARF)
Chromosomal deletion MF 2/50 (4%) Impaired DNA repair,
apoptosis and senescence
Navas53
CDKN2B Promoter hypermethylation
Chromosomal deletion
Promoter hypermethylation
MF
MF, Sz
4/49 (8%)
1/49 (2%)
30/66 (45%)
Diminished CDK
inhibitor activity, cell
cycle deregulation
Navas53
Scarisbrick52
CTSB Amplification
Amplification
MF, Sz
C-ALCL
5/7 (71%)
7/8 (88%)
Increased invasive
behaviour
Mao61
Mao45
Fas Point mutation
Point mutation
MF
MF
6/44 (14%)
3/16 (19%)
Disruption of extrinsic
apoptosis pathway
Dereure57
Nagasawa58
FGFR1 Amplification MF, Sz 4/7 (57%) Increased growth-factor
receptor signaling
Mao61
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HRAS Amplification MF, Sz 3/7 (43%) MAPK pathway, growth-
stimulation
Mao61
JUNB Amplification MF
Sz
C-ALCL
4/14 (29%)
4/22 (18%)
7/10 (70%)
Component of the AP-1
transcription factor,
regulating cell
proliferation
Mao61
MLH1 Promoter hypermethylation MF 9/51 (18%) Diminished DNA
mismatch repair
Scarisbrick50
MYBL2 Amplification MF, Sz 3/7 (43%) Oncogenic transcription
factor
Mao61
MYCL1 Amplification MF, Sz 3/7 (43%) Oncogenic transcription
factor
Mao61
MYCN Amplification C-ALCL 4/8 (50%) Oncogenic transcription
factor
Mao45
PAK1 Amplification MF, Sz 5/7 (71%) Altered regulation of
cytoskeletal dynamics
Mao61
PIK3CA Amplification MF, Sz 3/7 (43%) Deregulation of the PI3K
pathway promoting
survival
Mao61
PTEN Chromosomal deletion MF 10/44 (23%)
heterozygous
2/44 (5%)
homozygous
Deregulation of the PI3K
pathway, governing cell
cycle and apoptosis
Scarisbrick49
PTPN1 Amplification MF, Sz 4/7 (57%) Tyrosine phosphatase
activity
Mao61
PTPN6 Promoter hypermethylation Cell line from
C-ALCL
3/3 (100%) Loss of negative
regulation of cytokine
receptor Jak-Stat
pathways
Zhang78
RAF1 Amplification
Amplification
MF, Sz
C-ALCL
5/7 (71%)
7/8 (88%)
Stimulation of growth-
promoting MAPK
pathway
Mao61
Mao45
REL Amplification C-ALCL 6/8 (75%) NF-kB pathway, anti-
apoptotic
Mao45
TGFBR1 Deletion (intragenic) Cell line from
C-ALCL
1/1 (100%) Deregulation of SMAD
pathway, escape from
growth inhibition
Schiemann60
TGFBR2 Point mutation Cell line from
C-ALCL
1/1 (100%) Deregulation of SMAD
pathway, escape from
growth inhibition
Knaus61
TP53 Point mutation
Point mutation
Point mutation
Point mutation
Point mutation
CTCL
MF
MF
MF
MF
1/29 (3%)
6/29 (21%)
0/58 (0%)
0/9 (0%)
0/44 (0%)
Impaired DNA repair,
apoptosis and senescence
Garatti54
McGregor55
Kapur56
Navas53
Dereure57
YES1 Amplification C-ALCL 4/8 (50%) Src-family kinase,
growth-stimulatory
Mao45
ZNF217 Amplification MF, Sz 3/7 (43%) Oncogenic transcription
factor
Mao61
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apoptosis and senescence
Navas53
CDKN2B Promoter hypermethylation
Chromosomal deletion
Promoter hypermethylation
MF
MF, Sz
4/49 (8%)
1/49 (2%)
30/66 (45%)
Diminished CDK
inhibitor activity, cell
cycle deregulation
Navas53
Scarisbrick52
CTSB Amplification
Amplification
MF, Sz
C-ALCL
5/7 (71%)
7/8 (88%)
Increased invasive
behaviour
Mao61
Mao45
Fas Point mutation
Point mutation
MF
MF
6/44 (14%)
3/16 (19%)
Disruption of extrinsic
apoptosis pathway
Dereure57
Nagasawa58
FGFR1 Amplification MF, Sz 4/7 (57%) Increased growth-factor
receptor signaling
Mao61
  Table 2. continued
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Epigenetic factors in the pathogenesis 
of CTCL
In recent years it has increasingly been recog-
nized that in addition to genetic lesions, also epi-
genetic lesions are causally related to the devel-
opment and progression of cancer. Epigenetic 
refers to heritable information related to gene 
function not encoded in the nucleotide sequence. 
The main epigenetic mechanism in humans is 
DNA methylation, which refers to addition of a 
methyl-group to the cytosine nucleotide, where 
located adjacent to a guanosine in a CpG dinu-
cleotide. In normal human cells, CpG dinucleo-
tides present in repetitive sequences are meth-
ylated. CpG islands, sequences of hundreds of 
basepairs in length with a high density of CpG 
dinucleotides located in approximately half of all 
human gene promoters, are normally unmethyl-
ated with the exception of genes on the silenced 
X-chromosome in females, imprinted genes and 
several genes with tissue-speciﬁc expression. 
In cancer cells this DNA methylation pattern is 
severely perturbed: normally unmethylated CpG 
islands located in gene promoters may demon-
strate aberrant methylation, associated with 
silencing of these genes (promoter hypermeth-
ylation).63,64 This epigenetic mechanism of gene 
silencing may contribute to malignant transfor-
mation by inactivating tumor suppressor genes. 
Tumor types differ with respect to the frequency 
and patterns of promoter hypermethylation.65,66 
In addition, normally methylated CpG dinucleo-
tides present in repetitive sequences show loss 
of methylation (global hypomethylation), which 
is associated with chromosomal instability.67,68
A number of observations suggest that gene 
silencing associated with promoter hypermeth-
ylation has an important role in the pathogenesis 
of CTCL. Firstly, lymphomas in general show 
promoter hypermethylation of tumor suppressor 
genes at a higher frequency when compared with 
other tumor types.66,69 Secondly, chronic inﬂam-
mation is considered as a universal accelerator 
of DNA methylation, as indicated by studies 
in preneoplastic lesions of colon, oesophagus, 
liver and lung tissue.70-73 Tumors that develop 
in the setting of chronic inﬂammation, such as 
CTCL, are more likely to contain hypermethyl-
ated CpG islands.74 Thirdly, CTCL have been 
reported to respond favorably to treatment with 
histone deacetylase inhibitors (depsipeptide and 
suberanoylanilide hydroxamide).75 Aberrant 
transcriptional repression through histone modi-
ﬁcation and promoter hypermethylation are 
linked processes and often coincide.76,77 Consis-
tently, in the few studies performed thus far a 
number of genes relevant in the pathogenesis of 
CTCL have been demonstrated to be inactivated 
through promoter hypermethylation, including 
the CDKN2B, CDKN2A encoding p16(INK4A), 
MLH1 and PTPN6 (SHP-1) genes (see Table 
2).49-53,78
Deregulation of signaling pathways in CTCL 
Malignant transformation of cells is usually 
related to perturbation of signaling pathways 
that govern the regulation of proliferation, apop-
tosis and differentiation, such as the p53, Rb, 
PI3K, receptor tyrosine kinase, NF-kB, SMAD, 
JAK-STAT and mitochondrial apoptosis signal-
ing pathways.39 Deregulation of several signal-
ing pathways involved in malignant transforma-
tion due to altered expression or constitutive 
activity of their components has been identiﬁed 
in CTCL. In many cases however, no clear asso-
ciation with speciﬁc mutations or chromosomal 
abnormalities has been identiﬁed. In particu-
lar, defective apoptosis signaling is presumed 
to have an important role in the pathogenesis 
of CTCL, since apoptosis is the mechanism by 
which proliferating mature T cells are normally 
eliminated following stimulation with antigen. 
In addition, susceptibility to cellular immune 
responses directed towards malignant T cells 
depends on intact apoptotic pathways. As previ-
ously mentioned, engagement of the Fas receptor 
by Fas ligand activates a signaling pathway with 
a central role in the regulation of T cell apop-
tosis and homeostasis. In patients with tumor-
stage MF and CD30- LTCL expression of the 
Fas receptor protein on malignant T cells is fre-
quently lost.79 CTCL cells in early plaque-stage 
MF and C-ALCL however normally express the 
Fas receptor. 
Furthermore, several lines of evidence point to 
dysregulation of the signal transducer and acti-
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vator of transcription (STAT) family of tran-
scription factors in CTCL. Malignant T cells of 
patients with Sz and MF frequently demonstrate 
constitutive activity of STAT3.80,81 Activation of 
STAT3, observed in MF tumors but not in the 
early stages of MF, protects tumor cells from 
apoptosis in vitro.82 Promoter hypermethylation-
associated silencing of PTPN6 has been shown 
to be induced by activated STAT3 in malignant 
T cells and may in turn contribute to the consti-
tutive activation of this transcription factor.78,83 
Furthermore predominant expression of a trun-
cated isoform of STAT5 has been found in Sz. 
Expression of this STAT5 isoform has been 
related to suppression of the STAT5-dependent 
genes BCL2 and PIM1.84
Another signaling pathway reported to be dys-
regulated is the TNF receptor pathway. Using 
microarray analysis Tracey and colleagues iden-
tiﬁed 27 genes that were differentially expressed 
when comparing MF tumor biopsy samples with 
inﬂammatory dermatosis samples.85 Among the 
genes overexpressed in MF were TNFR-associ-
ated factor 1 (TRAF1) and TNFSF5 (CD40L), 
BIRC1 and BIRC3. The resultant deregulated 
signaling through TNFR1, TNFR2 and TNFR5 
is hypothesized to have anti-apoptotic as well 
as T cell costimulatory effects. In other studies 
co-expression of TNFR5 (CD40) and TNFSF5 
(CD40L, CD154), creating an autocrine loop, 
and increased expression of TNFSF10 (TRAIL) 
has been observed in CTCL.86,87 As previously 
mentioned, in C-ALCL and lymphomatoid 
papulosis signaling through the CD30 recep-
tor (TNFR8), a TNF receptor family member 
present on activated T cells, may contribute to 
the malignant phenotype.25
Additionally, loss of sensitivity to TGF-beta has 
been reported in CTCL, either due to diminished 
surface expression of the TGF-beta receptor 
protein in Sz or due to deleterious mutations in 
the TGF-beta receptor genes.59,60,88,89 The result-
ing disruption of the TGF-beta receptor signal-
ing pathway is associated with loss of growth 
inhibition by TGF-beta, an anti-proliferative and 
pro-apoptotic cytokine for lymphoid cells.90 
The immune environment in CTCL
The development and progression of CTCL 
appear to be determined in part by interactions 
with the immune micro-environment. Firstly, 
there is evidence to support that dendritic cells 
drive the proliferation of malignant T cells in 
CTCL, in particular during the early phases of 
the disease. In co-culture experiments it has been 
shown that immature dendritic cells stimulate 
the growth of CTCL cells.33 The exact nature of 
the co-dependency and stimulatory capacity of 
dendritic cells, including the question whether 
CTCL cells may recognize and be stimulated 
by antigen presented by dendritic cells, is as yet 
unclear.
Secondly, a number of observations suggest that 
a host anti-tumor immune response is crucial 
for controlling disease progression. Direct evi-
dence of the existence of an anti-tumor immune 
response in CTCL has been provided by Bagot 
and colleagues, who demonstrated that reactive 
lymphocytes present in lesional skin of a CTCL 
patient show cytotoxic activity toward fresh 
autologous neoplastic T cells.91 In addition, in 
sera of CTCL patients antibodies directed at 
CTCL-related antigens can be detected pointing 
to the existence of a humoral immune response 
against CTCL cells.92 Furthermore it has been 
noted that treatment of patients with MF with the 
immunosuppressive drugs cyclosporine, etaner-
cept or inﬂiximab can be associated with disease 
progression.93,94 Conversely immunomodulatory 
therapy aimed at augmenting a presumed anti- 
tumor immune response, such as interferon-
alpha, interleukin-12 and extracorporal pho-
topheresis, are efﬁcacious in the treatment 
of CTCL.95-97 Although the possibility is not 
excluded that these agents act directly upon 
the malignant T cells in CTCL, it is generally 
thought that modulation of the immune response 
directed against malignant T cells accounts for 
these effects. The fact that vaccination with 
CTCL-associated epitopes is capable of induc-
ing tumor regression underscores at least the 
potential of anti-tumor immune responses to 
inﬂuence disease evolution.98 Killing of target 
cells by cytotoxic T cells involves two mecha-
nisms: exocytosis of cytoplasmic granules con-
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taining cytotoxic proteins and interaction of Fas 
ligand expressed on the cytotoxic T cell and the 
Fas receptor on the target cell.99,100 Both of these 
stimuli activate an apoptotic signaling cascade 
in the neoplastic target cell (see Figure 2). The 
susceptibility of malignant T cells to cellular 
immune responses therefore depends on intact 
apoptotic pathways in these cells. 
In advanced forms of CTCL and Sz in particu-
lar, defective immune functioning occurs: the 
numbers of circulating CD8+ T cells, NK cells 
and dendritic cells are declined, the plasma 
levels of interleukin-12 and interferon-alpha -
cytokines that promote immune responses- are 
decreased, and the complexity of the T-cell 
repertoire is dramatically reduced.101-104 As a 
consequence, patients with CTCL are more sus-
ceptible to opportunistic infection. Moreover, 
this immune dysregulation may contribute to 
disease progression by diminishing the anti-
tumor immune response. 
The immune defects in CTCL are in part 
directly attributable to activity of the malig-
nant T-cell clone itself through the produc-
Fas Ligand
Fas (CD95)
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Procaspase 8
Caspase 8
Granzyme B
Perforin
Effector Caspase
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Apoptosis
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Figure 2. Apoptotic pathways activated by cytotoxic T cells.   
Apoptosis can occur via cell-surface-death-receptor- or mitochondrial-dependent pathways. Cytotoxic T cells can induce 
apoptosis in target cells, such as virally infected and neoplastic cells through the activation of death receptors on the surface of 
target cells or through the transfer of cytotoxic granules. Cytotoxic T cells express Fas ligand (FasL), which binds to the death 
receptor Fas on the target cell. Fas then recruits the Fas-associated death domain (FADD) adapter protein to form the death-
inducing signalling complex, causing the activation of aspase-8. Caspase-8, in turn, activates the downstream caspases, such 
as caspase-3, culminating in apoptosis. CTLs trigger a second pro-apoptotic pathway through the protease granzyme B, which, 
once released from CTLs, is translocated into the target cell by perforin. This allows granzyme B to have access to various 
cytoplasmic substrates and to cleave and activate downstream caspases. This ﬁgure was adapted from Thome et al.100
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tion of cytokines and expression of membrane 
molecules. Several studies suggest that CTCL 
cells originate from and display phenotypical 
characteristics of T helper 2 cells, including the 
production of cytokines such as interleukin-4, 
interleukin-5 and interleukin-10 compromising 
efﬁcient immune responses.105-108 More recently 
it was reported that malignant T cells of CTCL, 
when cultured with dendritic cells, may produce 
signiﬁcant levels of TGF-beta, interleukin-10 
and express CTLA-4 and FoxP3, features of T 
regulatory cells, an immunosuppressive subset 
of T cells.109
Aims and outline of the thesis
General aims of this thesis have been to iden-
tify clinicopathological determinants of disease 
progression of patients with CTCL and to gain 
more insight into the molecular pathogenesis of 
this group of T-cell malignancies.
In the ﬁrst part of the thesis (chapter 2, 3 and 
4) issues are addressed that relate to the disease 
course of CTCL and clinicopathological factors 
that may determine and predict disease progres-
sion. This part of the study has been facilitated 
by the Dutch Cutaneous Lymphoma Group 
(DCLG). The DCLG consists of an expert panel 
of dermatologists and pathologists meeting on a 
regular basis to discuss and reach agreement on 
the diagnosis of Dutch patients presented with 
cutaneous lymphoma. Clinical characteristics 
and disease course data of patients are included 
in the registry of the DCLG. The fact that almost 
all Dutch patients with cutaneous lymphoma are 
registered by the DCLG allows unbiased clini-
cal epidemiological studies. The department of 
Dermatology of the Leiden University Medical 
Center is the nation-wide referral center for 
CTCL patients and responsible for the registry of 
the DCLG. Biopsy specimens of many patients 
with cutaneous lymphoma are therefore availa-
ble for studies of the pathological and molecular 
biological aspects of this group of lymphomas.
In the ﬁrst part of the thesis we addressed the 
following issues:
- Although general survival ﬁgures for patients 
with MF are available from epidemiological 
studies conducted in the United States, more 
speciﬁc information regarding the disease 
course stratiﬁed per clinical stage is limited. 
In chapter 2 we investigated the frequency of 
occurrence of disease progression from skin-
limited to widespread disseminated disease as 
well as the survival of patients diagnosed with 
MF in The Netherlands. In addition, we evalu-
ated which clinical features are associated with 
an aggressive disease course and unfavorable 
prognosis.
- Results from the study presented in chapter 
2 reinforced the clinical impression that fol-
liculotropic MF has a more aggressive clini-
cal behavior than the classic epidermotropic 
type of MF. In chapter 3 we report a detailed 
description of the clinical features, histopatho-
logical alterations and prognosis of a large 
cohort of patients with folliculotropic MF.
- There are many indications that the disease 
course of CTCL patients is partly determined 
by an anti-tumor immune response mounted 
by cytotoxic CD8+ T cells. In chapter 4 we 
studied the relationship between the number of 
reactive CD8+ T cells relative to neoplastic T 
cells in CTCL skin lesions and the prognosis.
In the second part of the thesis (chapter 5, 6 and 
7) attempts were made to identify genetic and 
epigenetic features of the malignant T cells that 
are relevant in the development and progression 
of these lymphomas. In two studies microar-
ray technology was applied to investigate gene 
expression and promoter hypermethylation pat-
terns in neoplastic T cells of CTCL patients. 
Microarray technology enables a more com-
plete experimental approach where the level of 
gene expression, the presence of cytogenetic 
abnormalities or the occurrence of DNA meth-
ylation can be assayed simultaneously in entire 
genomes.110 Gene expression proﬁling, the most 
widely used genomic technology, has reﬁned 
the classiﬁcation of hematological malignan-
cies, has given insight into the pathogenesis and 
has revealed novel therapeutic targets.111,112 The 
principle of microarray-based analysis has been 
extended to the genome-wide study of DNA 
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Figure 3. Preparation of RNA en DNA for gene expression and DNA methylation proﬁling.     
For gene expression analysis using oligonucleotide microarrays (Affymetrix) RNA is extracted from tumor tissue and reverse 
transcribed to yield complementary DNA. After second strand synthesis, the puriﬁed cDNA product is in vitro transcribed 
using T7 RNA polymerase, biotin-UTP and biotin-CTP to generate biotinylated aRNA. The fragmented aRNA is hybridized 
to an oligonucleotide microarray that contains short 25-mer oligonucleotide probes, that are photolithographically synthesized 
on the microarrays.
To detect methylated sequences, DNA isolated from tumor tissue is digested by MseI to obtain DNA fragments of a few hundred 
bp in length, to which linkers are ligated. These linker-ligated fragments are then sequentially digested by two methylation-
sensitive restriction enzymes (BstUI and HpaII). Hypermethylated sequences, refractory to cleavage by the methylation 
sensitive enzymes, are then selectively ampliﬁed in a linker-PCR, ﬂuorescently labeled and subsequently hybridized to the 
CpG island microarray. This microarray contains as probes a panel of 8640 CpG island tags, 200-2000 bp in length, prepared 
from a genomic library arrayed on a glass slide.
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methylation.113,114 In microarray experiments, 
target cDNA, cRNA or genomic DNA is labeled 
with a ﬂuorescent dye and hybridized to DNA 
probes arrayed on a platform such as a glass 
slide (Figure 3). A scanner then measures ﬂuo-
rescence at the site of each probe corresponding 
to the abundance of the interrogated transcript 
or DNA sequence. 
In the second part of the thesis we examined the 
following:
- Deregulated activity of the Fas signaling 
pathway has been suspected in CTCL, based 
on the central role of Fas-induced apoptosis in 
the homeostasis of mature T-cells and in con-
ferring susceptibility to anti-tumor immune 
responses. Diminished Fas protein expression 
has been demonstrated in advanced stages of 
MF.79 The function of Fas may be disrupted 
in cancer cells through point mutations or 
alternative splicing of the gene encoding this 
apoptosis-inducing receptor.115-118 In chapter 5 
we analyzed whether Fas gene alterations are 
present in neoplastic T cells of CTCL patients. 
- The gene expression pattern that distinguishes 
malignant T cells of CTCL patients from 
benign T cells promises to give insight into the 
signaling alterations relevant to the develop-
ment and progression of CTCL. In chapter 6 
we performed microarray-based gene expres-
sion analysis on isolated T cells of patients with 
Sézary syndrome with the additional purpose 
of identifying tumor-associated markers for 
the molecular diagnosis and directed therapy 
of CTCL.
- Several observations suggest that promoter 
hypermethylation, associated with inactiva-
tion of tumor suppressor genes, may be an 
important factor in the pathogenesis of CTCL. 
The purpose of the study presented in chapter 
7 was to analyze the occurrence of promoter 
hypermethylation in CTCL on a genome-wide 
scale, focusing on pathogenetically signiﬁcant 
epigenetic alterations. 
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